Spots Global Cancer Trial Database for Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

Official Title: A Prospective Study of Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy With or Without Mediastinal Irradiation

Study ID: NCT00165438

Conditions

Hodgkin's Disease

Interventions

Pulmonary Function Tests

CAT Scan

Study Description

Brief Summary: The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.

Detailed Description: * The tests and procedures in this study are part of regular cancer care but this study offers more structured timing of these standard tests. * Due to the potential lung toxicity associated with bleomycin-based chemotherapy, pulmonary function tests are routinely performed. Pulmonary function tests will be performed by a licensed, registered respiratory therapist and performed prior to the beginning of treatment, between the chemotherapy and radiation therapy (only for patients receiving both chemotherapy and radiation therapy), and at approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * A CAT scan will be performed prior to the beginning of treatment, and approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * A self-administered questionnaire will be performed on the days the patient is undergoing pulmonary function tests.